Tessera Therapeutics Announces Over $300M Series C Financing To Advance Its Gene Writing Platform
Amount Raised
$300 Million
Round Type
Series C
SomervilleSoftwareHealth CareScience And EngineeringDescription
Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing. Investors included a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Alaska Permanent Fund Corporation; Altitude Life Science Ventures; ARTIS Ventures; Cormorant Asset Management; Tessera’s founder, Flagship Pioneering; Hanwha Impact Partners; Longevity Vision Fund; March Capital; SALT Fund; SoftBank Vision Fund 2; funds and accounts advised by T. Rowe Price Associates, Inc., and others including all of Tessera’s existing institutional shareholders.
Quick answer
Tessera Therapeutics raised $300 Million in a Series C round, dated April 19, 2022. Tessera Therapeutics is based in Somerville, Massachusetts, United States.
- How much did Tessera Therapeutics raise?
- Tessera Therapeutics raised $300 Million in a Series C round on April 19, 2022.
- What does Tessera Therapeutics do?
- Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome,..
- Where is Tessera Therapeutics based and how big is it?
- Tessera Therapeutics is based in Somerville, Massachusetts, United States.
- Who are the decision-makers at Tessera Therapeutics?
- Fundz holds 1 contact at Tessera Therapeutics, including the Chief Human Resources Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Software around the same time
Companies in the same sectors as Tessera Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Sequentify raised $7M (Funding Round) on May 10, 2022.
- IMPLICITY raised $23M (Funding Round) on April 27, 2022.
- Ensem Therapeutics raised $67M (Series A) on April 6, 2022.
- Clarify Health raised $150M (Series D) on April 5, 2022.
- Zephyr AI, Inc. raised $18M on April 4, 2022.
- Zephyr AI, Inc. raised $19M (Seed) on March 30, 2022.
Who to call at Tessera Therapeutics, and when
A new round usually means Tessera Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tessera Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tessera Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tessera Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tessera Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Tessera Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.